Alex Zopo, MD
Internal Medicine · Boynton Beach, FLNPI 1184658718
Payments from drug & device makers
Across 221 payments — averaging $10,428 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endo Pharmaceuticals Inc.$1.5M
- Sumitomo Pharma America, Inc.$632K
- Novavax Inc$118K
- Acerus Pharmaceuticals Corporation$5K
- Bayer$250
- Astellas Pharma US Inc$203
- plus $2K from 34 others
What the payments were for
- Food & beverage$2,48799%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endo Pharmaceuticals Inc. | 48 | $1,547,170 |
| Sumitomo Pharma America, Inc. | 41 | $632,160 |
| Novavax Inc | 19 | $117,633 |
| Acerus Pharmaceuticals Corporation | 3 | $5,040 |
| Bayer | 12 | $250 |
| Astellas Pharma US Inc | 10 | $203 |
| W. L. Gore & Associates, Inc. | 1 | $186 |
| AstraZeneca | 3 | $176 |
| Novo Nordisk | 10 | $156 |
| Amgen | 7 | $130 |
| Boston Scientific | 4 | $125 |
| Abbott | 5 | $110 |
| Johnson & Johnson | 6 | $100 |
| AbbVie(2 entities) | 5 | $90 |
| Lilly USA, LLC | 5 | $88 |
| Pfizer | 4 | $74 |
| GSK | 4 | $62 |
| Saluda Medical Americas, Inc. | 1 | $54 |
| Medtronic | 1 | $52 |
| Novartis | 3 | $52 |
| Edwards Lifesciences | 2 | $51 |
| Atricure, Inc. | 2 | $49 |
| Stryker | 1 | $44 |
| Smith+Nephew | 1 | $44 |
| Boehringer Ingelheim | 3 | $42 |
| E.r. Squibb & Sons, L.L.C. | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 2 | $37 |
| Genentech USA, Inc. | 2 | $33 |
| Eisai Inc. | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Corcept Therapeutics | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Biosense Webster, Inc. | 1 | $23 |
| Exact Sciences | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- C3 Delivery System$186
- AIRSUPRA$129
How this compares
$2,304,505 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 142 | $165,964 |
| XareltoRivaroxaban | 64 | $75,517 |
| OzempicSemaglutide | 27 | $36,370 |
| JardianceEmpagliflozin | 18 | $30,950 |
| RybelsusSemaglutide | 17 | $29,451 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $26,655 |
| JanuviaSitagliptin Phosphate | 16 | $25,925 |
| MounjaroTirzepatide | 22 | $22,364 |
| EntrestoSacubitril/Valsartan | 11 | $18,940 |
| OxycontinOxycodone Hcl | 13 | $13,061 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $11,258 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $10,918 |
| VascepaIcosapent Ethyl | 11 | $10,188 |
| Levothyroxine Sodium | 703 | $8,006 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 195 | $6,496 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $74 | $171,620164 claims |
| Johnson & JohnsonXarelto | $100 | $75,51764 claims |
| Novo NordiskOzempic, Rybelsus | $156 | $65,82144 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $62 | $37,91341 claims |
| Boehringer IngelheimJardiance | $42 | $30,95018 claims |
| MerckJanuvia | $14 | $25,92516 claims |
| Lilly USA, LLCMounjaro | $88 | $22,36422 claims |
| NovartisEntresto | $52 | $18,94011 claims |
| AstraZenecaSymbicort, Brilinta | $176 | $16,12230 claims |
| AbbVieSynthroid | $90 | $4,89468 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Boynton Beach
- Debra WeinsteinBoynton Beach$14.8M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.